[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Benjamin J. Zeskind M.B.A., Ph.D.", "age": 40, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 898416, "exercisedValue": 0, "unexercisedValue": 374440}, {"maxAge": 1, "name": "Dr. Brett M. Hall Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 867917, "exercisedValue": 0, "unexercisedValue": 453376}, {"maxAge": 1, "name": "Ms. Mallory  Morales CPA", "age": 38, "title": "Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer", "yearBorn": 1984, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula  George CPA", "title": "Director of Accounting & Operations and Assistant Corporate Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Bookman J.D.", "age": 34, "title": "Chief Legal Officer & Secretary", "yearBorn": 1988, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah R. Neufeld", "age": 50, "title": "Chief People Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  King Ph.D.", "title": "Head of Discovery & VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Praveen  Nair Ph.D.", "title": "Head of Translational Pharmacology & VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harold E. Brakewood", "age": 57, "title": "Chief Business Officer", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Sebastian CPA", "title": "Executive Director & Corporate Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1701388800, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.48, "open": 7.4, "dayLow": 7.21, "dayHigh": 7.795, "regularMarketPreviousClose": 7.48, "regularMarketOpen": 7.4, "regularMarketDayLow": 7.21, "regularMarketDayHigh": 7.795, "payoutRatio": 0.0, "beta": -0.816, "forwardPE": -3.7563453, "volume": 82817, "regularMarketVolume": 82817, "averageVolume": 65308, "averageVolume10days": 90190, "averageDailyVolume10Day": 90190, "bid": 5.0, "ask": 7.82, "bidSize": 800, "askSize": 800, "marketCap": 216591344, "fiftyTwoWeekLow": 3.7, "fiftyTwoWeekHigh": 14.29, "priceToSalesTrailing12Months": 476024.94, "fiftyDayAverage": 6.5516, "twoHundredDayAverage": 8.545925, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 126233168, "profitMargins": 0.0, "floatShares": 14911446, "sharesOutstanding": 29269100, "sharesShort": 2568003, "sharesShortPriorMonth": 2794053, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0877, "heldPercentInsiders": 0.2761, "heldPercentInstitutions": 0.58139, "shortRatio": 35.38, "shortPercentOfFloat": 0.16389999, "impliedSharesOutstanding": 29269100, "bookValue": 3.554, "priceToBook": 2.082161, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -51633692, "trailingEps": -1.86, "forwardEps": -1.97, "enterpriseToRevenue": 277435.53, "enterpriseToEbitda": -2.264, "52WeekChange": 0.7116705, "SandP52WeekChange": 0.26208627, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "messageBoardId": "finmb_308350677", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.4, "targetHighPrice": 25.0, "targetLowPrice": 10.0, "targetMeanPrice": 18.75, "targetMedianPrice": 20.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 97242512, "totalCashPerShare": 3.322, "ebitda": -55756716, "totalDebt": 4542653, "quickRatio": 17.296, "currentRatio": 17.89, "totalRevenue": 455, "debtToEquity": 4.367, "revenuePerShare": 0.0, "returnOnAssets": -0.28323, "returnOnEquity": -0.45712003, "grossProfits": 158830, "freeCashflow": -31446908, "operatingCashflow": -48942048, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -123287.71, "financialCurrency": "USD", "trailingPegRatio": null}]